Advancing Immunotherapy in the Kansas City Region: Chimeric Antigen Receptors Targeting Cancer and Beyond
As we reach limits of toxicity and efficacy related to traditional anti-cancer modalities such as chemotherapy and radiation, new, less toxic, more efficacious therapies are needed and sought. Immunotherapy in the form of small molecule immunomodulatory agents, complex biologics such as targeted antibodies, cancer vaccines and other forms of cell based immunotherapeutics are coming of age. Chimeric antigen receptor (CAR) technology is one promising modality that has sparked significant interest in cancer immunotherapy. The CAR is a complex protein that, when expressed by an immune effector cell such as a T-lymphocyte or natural killer cell, can redirect the cytotoxicity of the cell from a traditional target, such as a virally infected cell, toward a cancer cell. I will present the state of CAR therapy in this region and give an overview of work designed to develop novel immunotherapeutics in the region. Presentations over the next few weeks will focus on a collaboration designed to advance CAR therapy in human and animal malignancy and illustrate how this collaboration has fostered relationships with other investigators and institutions to advance this project and efforts in other areas of immunotherapeutics.
Speaker- Doug Myers, MD
Doug Myers, MD is an Associate Professor of Pediatrics at Children’s Mercy Hospital/University of Missouri Kansas City in the Division of Hematology/Oncology/Stem Cell Transplantation. He is the Director of Innovation in Cellular Therapeutics and is charged with advancing cell based immunotherapeutics for the hospital. Clinically, he treats pediatric patients with hematopoietic stem cell transplantation and has developed and been primary investigator on several novel, complex immunotherapeutic clinical trials. He received his MD from the University of Oklahoma College of Medicine and did his pediatric hematology/oncology fellowship at Texas Children’s Hospital/Baylor College of Medicine in Houston, TX where he did research in cell based immunotherapeutics at the Center for Cell and Gene Therapy.
Kauffman Foundation Conference Center
4801 Rockhill Rd, Kansas City, MO 64110
Or virtually via “Zoom”